Related Experiment Video
Updated: Jul 22, 2026
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
Synthesis and evaluation of biarylquinoline derivatives as novel HIF-1α inhibitors
Yu-Chieh Wu1, Meng-Tien Lu2, Tai-Hui Lin1
1School of Pharmacy, College of Pharmacy, China Medical University, Taichung 40402, Taiwan.
Abstract:
Hypoxia-inducible factor (HIF)-1α is a key transcription factor that contributes to aggressive and drug-resistant phenotypes in tumor cells under hypoxic conditions. Therefore, targeting HIF-1α represents a promising therapeutic strategy for cancer drug development. In the present study, we designed, synthesized, and evaluated a new series of biarylquinoline derivatives as potential HIF-1α inhibitors based on structure-activity relationship. Among these derivatives, compound 7f represents the optimal agent with IC50 values of 28 nM and 15 nM in suppressing the viability of MiaPaCa-2 and MDA-MB-231 cells, respectively. Compound 7f also exhibited potent efficacy in inhibiting hypoxia-induced migration of MDA-MB-231 and MiaPaCa-2 cells. Mechanistically, compound 7f suppressed HIF-1α expression by blocking transcription and protein translation, in lieu of facilitating protein degradation. Moreover, this HIF-1α downregulation was associated with compound 7f's ability to concomitantly inhibit multiple signaling pathways governing HIF-1 α expression at different levels, including those mediated by STAT3, MEK/ERK MAPK, and mTOR/4E-BP1. Together, these findings underscore the translational potential of these biarylquinoline derivatives to be developed as novel HIF-1α inhibitors, which warrants further investigations.
Insights
Researchers developed novel biarylquinoline derivatives as inhibitors of hypoxia-inducible factor (HIF)-1α. Compound 7f effectively suppressed cancer cell viability and migration by blocking HIF-1α expression and related signaling pathways.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Hypoxia-inducible factor (HIF)-1α promotes tumor aggressiveness and drug resistance.
- Targeting HIF-1α is a key strategy in cancer therapy development.
Purpose of the Study:
- To design, synthesize, and evaluate novel biarylquinoline derivatives as HIF-1α inhibitors.
- To identify potent compounds for targeting cancer phenotypes driven by HIF-1α.
Main Methods:
- Structure-activity relationship (SAR) studies guided the design of biarylquinoline derivatives.
- In vitro assays assessed compound efficacy in suppressing cancer cell viability and migration.
- Mechanistic studies investigated the impact of compounds on HIF-1α expression and signaling pathways.
Main Results:
- Compound 7f demonstrated potent inhibition of MiaPaCa-2 and MDA-MB-231 cell viability (IC50 values of 28 nM and 15 nM, respectively).
- Compound 7f effectively inhibited hypoxia-induced cancer cell migration.
- Mechanistically, compound 7f suppressed HIF-1α expression by blocking transcription and translation, not protein degradation.
- Compound 7f inhibited multiple signaling pathways (STAT3, MEK/ERK MAPK, mTOR/4E-BP1) regulating HIF-1α.
Conclusions:
- Biarylquinoline derivatives, particularly compound 7f, show significant potential as novel HIF-1α inhibitors.
- These findings support the translational development of these compounds for cancer treatment.
- Further investigations are warranted to explore their therapeutic applications.
Related Concept Videos
01:28Inhibitors of Bacterial DNA Synthesis
01:30Inhibitors of Viral Protein Synthesis
01:22Antiviral Nucleoside Inhibitors